ATA Guidelines Tools

Medullary Thyroid Carcinoma

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/540772

Contents of this Issue

Navigation

Page 5 of 17

4 Diagnosis Table 2. Relationship of Common RET Mutations to Risk of Aggressive MTC in MEN2A and MEN2B and to the Incidence of PHEO, HPTH, CLA and HD in MEN2A RET Mutation Exon MTC risk level a Incidence of PHEO b Incidence of HPTH b CLA c HD A883F 15 H +++ - N N C609F/G/R/S/Y 10 MOD +/++ + N Y C611F/G/S/Y/W 10 MOD +/++ + N Y C620F/R/S 10 MOD +/++ + N Y C634F/G/R/S/W/Y 11 H +++ ++ Y N D631Y 11 MOD +++ - N N E768D 13 MOD - - N N G533C 8 MOD + - N N K666E 11 MOD + - N N L790F 13 MOD + - N N M918T 16 HST +++ - N N R912P 16 MOD - - N N S891A 15 MOD + + N N V804L 14 MOD + + N N V804M 14 MOD + + Y N a Risk of aggressive MTC: MOD=Moderate, H=High, HST= Highest b Incidence of PHEO and HPTH, c Y=positive occurrence, N=negative occurrence: + = ~10%, ++ = ~20-30%, +++ = ~50%. e references for each of the RET mutations can be found in the Supplemental Information, where all reported RET mutations in MTC are listed. [www.thyca.org/download/document/280/ MTCguidelines.pdf ]

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Medullary Thyroid Carcinoma